In the Claims

Please substitute the following claim 1 for the claim 1 now pending in the above-identified application.

Please cancel claims 25-28.

Please add new claims 50-53.

- 1. (Currently Amended) An orally disintegrable tablet which comprises
 - (i) fine granules having an average particle diameter of 400 µm or less, which fine granules comprise a composition coated by an enteric coating layer comprising a first component which is an enteric coating agent and a second component which is a sustained release agent, said composition having 10 weight % or more of an acid-labile physiologically active substance and
 - (ii) a water-soluble sugar alcohol, erystalline cellulose, low-substituted hydroxypropyl cellulose or a combination thereof

wherein the water-soluble sugar alcohol is in an amount of 5 to 97 weight % relative to 100 weight % of the orally disintegrable tablet apart from the fine granules;

wherein said tablet having a hardness strength of about 1 to about 20 kg is orally disintegrable;

and wherein the oral disintegration time of said tablet is one minute or less.

- 2. (Original) An orally disintegrable tablet of claim 1, wherein the average particle diameter of the fine granules is 300 to 400 µm.
- 3. (Original) An orally disintegrable tablet of claim 1, wherein the fine granules further comprise a basic inorganic salt.

Claim 4 (Cancelled)

5. (Original) An orally disintegrable tablet of claim 1, wherein the composition coated by an enteric coating layer is further coated by a coating layer which comprises a water-soluble sugar alcohol.

Claim 6 (Cancelled)

7. (Original) An orally disintegrable tablet of claim 1, wherein the particle diameter of the fine granules is practically 425 µm or less.

Claim 8 (Cancelled)

9. (Original) An orally disintegrable tablet of claim 1, wherein the acid-labile physiologically active substance is a benzimidazole compound or a salt thereof.

Claim 10 (Cancelled)

- 11. (Original) An orally disintegrable tablet of claim 3, wherein the basic inorganic salt is a salt of magnesium and/or a salt of calcium.
- 12. (Original) An orally disintegrable tablet of claim 1, wherein the composition comprises a core being coated by a benzimidazole compound and a basic inorganic salt, said core comprising crystalline cellulose and lactose.
- 13. (Original) An orally disintegrable tablet of claim 12, wherein the core comprisesU.S. Patent Application Serial No. 10/017,755

50 weight % or more of lactose.

- 14. (Original) An orally disintegrable tablet of claim 12, wherein the core comprises 40 to 50 weight % of crystalline cellulose and 50 to 60 weight % of lactose.
- 15. (Original) An orally disintegrable tablet of claim 1, wherein the composition comprises 20 weight % or more of an acid-labile physiologically active substance.
- 16: (Original) An orally disintegrable tablet of claim 1, wherein the composition comprises 20 to 50 weight % of an acid-labile physiologically active substance.
- 17. (Original) An orally disintegrable tablet of claim 1, wherein the fine granules are produced by fluidized-bed granulation method.
- 18. (Original) An orally disintegrable tablet of claim 1, wherein the enteric coating layer comprises an aqueous enteric polymer agent.
- 19. (Original) An orally disintegrable tablet of claim 18, wherein the aqueous enteric polymer agent is a methacrylate copolymer.

Claim 20 (Cancelled)

21. (Previously Presented) An orally disintegrable tablet of claim 1, wherein the sustained-release agent is a methacrylate copolymer.

- 22. (Previously Presented) An orally disintegrable tablet of claim 1, wherein the sustained-release agent is in an amount of 5 to 15 weight % relative to 100 weight % of the aqueous enteric polymer agent.
- 23. (Previously Presented) An orally disintegrable tablet of claim 1, wherein the water-soluble sugar alcohol is erythritol.
- 24. (Previously Presented) An orally disintegrable tablet of claim 1, wherein the water-soluble sugar alcohol is mannitol.

Claims 25-28 (Cancelled)

29. (Original) An orally disintegrable tablet of claim 1, which further comprises crospovidone.

Claim 30 (Cancelled)

31. (Original) An orally disintegrable tablet of claim 1, which comprises no lubricant inside the tablet.

Claims 32-49 (Cancelled)

50. (New) An orally disintegrable tablet of claim 1, wherein an additive selected from U.S. Patent Application Serial No. 10/017,755

crystalline cellulose, low substituted hydroxypropyl cellulose or a combination thereof is further comprised in combination with said water-soluble sugar alcohol.

- 51. (New) An orally disintegrable tablet of claim 50, wherein the crystalline cellulose is in an amount of 3 to 50 weight % relative to 100 weight % of the tablet apart from the fine granule.
- 52. (New) An orally disintegrable tablet of claim 50, wherein the content of hydroxypropoxyl group in the low-substituted hydroxypropyl cellulose is 7.0 to 9.9 weight %.
- 53. (New) An orally disintegrable tablet of claim 50, wherein the content of hydroxypropoxyl group in the low-substituted hydroxypropyl cellulose is 5.0 to 7.0 weight %.